Speakers
Jim Brown
Chief Executive Officer
DURECT
Day Two
Thursday, July 15, 2021
1:00 pm | DUR-928, DNMTs and Alcohol-Associated Hepatitis
A. Ganesan
Professor
University of East Anglia
Day Two
Thursday, July 15, 2021
10:00 am | Targeting Two Erasers: Dual Inhibition of HDACs and LSD1
Gerd Hummel
Director of Drug Development
Oryzon Genomics
Michael-Christopher Keogh
Chief Scientific Officer
Epicypher
Day One
Wednesday, July 14, 2021
11:40 am | Next generation genomic mapping with CUTANA CUT&RUN
Ibrahim Jivanjee
Director of Product Management and Marketing
Arima Genomics, Inc
Day One
Wednesday, July 14, 2021
12:50 pm | Leverage the spatial properties of the genome to discover translational markers towards novel diagnostics, therapies and treatments.
Neil Michaud
Senior Director of Translational Medicine
Epizyme, Inc.
Day One
Wednesday, July 14, 2021
2:30 pm | Molecular Correlates of Response to TAZVERIK®: the Value of Translational Studies
Eric Campeau
Senior Director of Translational Medicine
Zenith Epigenetics
Day Two
Thursday, July 15, 2021
3:30 pm | Clinical Development of The BET Bromodomain Inhibitor ZEN- 3694 In Solid Tumors: Lessons Learned
Maria Hatziapostolou
Senior Lecturer
Nottingham Trent University
Day One
Wednesday, July 14, 2021
11:50 am | "Breaking” a lncRNA-Protein Complex as a Novel Approach to Target Cancer Metabolism
Iain Russell
Director of Marketing
Dovetail Genomics
Day One
Wednesday, July 14, 2021
11:00 am | From Mechanism of Action to Biomarker Discovery – how chromatin landscape informs the drug discovery process.
Ellen Filvaroff
Executive Director in Translational Development
Bristol-Myers Squibb
Day Two
Thursday, July 15, 2021
11:00 am | CC-90011, a Potent, Oral, & Reversible LSD1 Inhibitor
Elisabetta Chiarparin
Director - Medicinal Chemistry
AstraZeneca
Day Two
Thursday, July 15, 2021
2:00 pm | Discovery of Small Molecule Modulators of Epi Targets
Zariana Nikolova
Executive Director
Bristol Myers Squibb
Day Two
Thursday, July 15, 2021
11:00 am | CC-90011, a Potent, Oral, & Reversible LSD1 Inhibitor
Sylvie Guichard
Senior Director - Translational Science & Biology
Forma Therapeutics
Day One
Wednesday, July 14, 2021
1:30 pm | A Novel CBP/p300 Inhibitor for the Treatment of AR-driven Cancers
Drew Thompson
Vice President - Molecular Innovation & Pharmaceutical Development
Fulcrum Therapeutics
Day Two
Thursday, July 15, 2021
2:30 pm | Next Generation Drug Discovery at Fulcrum Therapeutics: FTX-6058, A Novel EED Inhibitor To Increase Fetal Hemoglobin Expression For the Treatment of Select Hemoglobinopathies
Chih-Ming Ho
Chief Technology Officer
KYAN Therapeutics
Day Two
Thursday, July 15, 2021
9:30 am | Global Optimization of Combinatorial Drug Enable by AI-PRS Platform
Johnathan R. Whetstine, PhD
Professor, Jack Schultz Basic Science Endowed Chair Director, Cancer Epigenetics Institute Program Co-leader Cancer Signaling and Epigenetics
Fox Chase Cancer Center
Day Two
Thursday, July 15, 2021
9:00 am | Epigenetics: A Gatekeeper for DNA Replication & ecDNA Amplification
Kai He
Assistant Professor of Medicine
Ohio State University Comprehensive Cancer
Day Two
Thursday, July 15, 2021
12:00 pm | Transitioning from Haematological to Solid Tumors
James Winkler
Vice President - Biology & Translational Medicine
OnKure Inc.
Day One
Wednesday, July 14, 2021
1:00 pm | OKI-179, an Oral Class 1-selective Depsipeptide HDAC Inhibitor: Phase 1 Results & Phase 2 Plans
Xuedong Liu
Professor, Department of Biochemistry, University of Colorado-Boulder and Co-Founder and SAB
OnKure Inc.
Day One
Wednesday, July 14, 2021
9:30 am | Panel Discussion - HDAC3, BET, RNA, So Many Targets – Exploring New Potential in Well Known Targets to Create New Value & Diversify Pipelines
Tamara Maes
Founder, Shareholder, VP of Board of Directors, & President of Scientific Advisory Board
Oryzon Genomics
Robert Soliva
Head of Drug Discovery
Oryzon Genomics
Day One
Wednesday, July 14, 2021
9:30 am | Panel Discussion - HDAC3, BET, RNA, So Many Targets – Exploring New Potential in Well Known Targets to Create New Value & Diversify Pipelines
Thomas Paul
Senior Director, Epigenetics Research
Pfizer
Day One
Wednesday, July 14, 2021
3:00 pm | Discovery of a First-in-Class KAT6A/KAT6B Inhibitor CTX-648 (PF-9363) with Potent Anti-Tumor Activity in ER+ Breast Cancer with KAT6A Dysregulation
9:30 am | Panel Discussion - HDAC3, BET, RNA, So Many Targets – Exploring New Potential in Well Known Targets to Create New Value & Diversify Pipelines
Aundrietta Duncan
Director, Non-Clinical Development
Salarius Pharmaceuticals
Day One
Wednesday, July 14, 2021
3:30 pm | Targeting FET-Rearranged Sarcomas Through Inhibition of LSD1
Alon Goren
Assistant Professor
University of California San Diego
Day Two
Thursday, July 15, 2021
4:00 pm | Designing Biomarkers That Enable Accurate Translation of Combination Therapies
Jiuzhou Song
Professor
University of Maryland
Day One
Wednesday, July 14, 2021
4:00 pm | Noncoding RNA & Epigenetics in Animal Health
Antonello Mai
Professor
University of Rome La Sapienza
Day Two
Thursday, July 15, 2021
11:30 pm | Epi-drugs in Parasites
Nikhil Ghate
Postdoctoral Research Associate
University of Southern California
Day One
Wednesday, July 14, 2021
10:00 am | Targeting Histone H2AThr120 Phosphorylation in Colon Cancer
Laura Banaszynski
Principal Investigator
University of Texas Southwestern Medical Center
Day Two
Thursday, July 15, 2021
1:30 pm | Phosphorylation of Histone H3.3 at Serine 31 Promotes p300 Activity
Ari Melnick
Professor
Weill Cornell - Cornell University
Day One
Wednesday, July 14, 2021